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Abstract
Rationale Standardized Field Sobriety Tests (SFST) and
oral fluid devices are used to screen for driving impairment
and roadside drug detection, respectively. SFST have been
validated for alcohol, but their sensitivity to impairment
induced by other drugs is relatively unknown. The sensitiv-
ity and specificity for Δ9-tetrahydrocannabinol (THC) of
most oral fluid devices have been low.
Objective This study assessed the effects of smoking
cannabis with and without alcohol on SFST perfor-
mance. Presence of THC in oral fluid was examined
with two devices (Dräger Drug Test® 5000 and Secure-
tec Drugwipe® 5).
Methods Twenty heavy cannabis users (15 males and 5
females; mean age, 24.3 years) participated in a double-
blind, placebo-controlled study assessing percentage of im-
paired individuals on the SFST and the sensitivity of two
oral fluid devices. Participants received alcohol doses or
alcohol placebo in combination with 400 μg/kg body weight
THC. We aimed to reach peak blood alcohol concentration
values of 0.5 and 0.7 mg/mL.
Results Cannabis was significantly related to perfor-
mance on the one-leg stand (p00.037). Alcohol in com-
bination with cannabis was significantly related to
impairment on horizontal gaze nystagmus (p00.029).
The Dräger Drug Test® 5000 demonstrated a high sen-
sitivity for THC, whereas the sensitivity of the Secure-
tec Drugwipe® 5 was low.
Conclusions SFST were mildly sensitive to impairment
from cannabis in heavy users. Lack of sensitivity might
be attributed to tolerance and time of testing. SFST
were sensitive to both doses of alcohol. The Dräger
Drug Test® 5000 appears to be a promising tool for
detecting THC in oral fluid as far as correct THC
detection is concerned.
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Cannabis is one of the most widely used illicit drugs. About
16.7 million persons or 6.6 % of the USA general popula-
tion aged 12 and older admitted to past month use (Sub-
stance Abuse and Mental Health Services Administration
2010). In Europe, past month users aged 15–64 years was
estimated to be 12.5 million (3.7 %) (European Monitoring
Centre for Drugs and Drug Addiction 2010). Because of its
widespread use, the prevalence of cannabis in the general
driving population is also one of the highest after alcohol,
with driving under the influence of cannabis (DUIC) being
2.4 % of the general driving population (EMCDDA 2008).
Among young drivers, the prevalence of DUIC was even
30 %. This is a serious cause for concern since experimental
and epidemiological studies have shown that cannabis im-
paired driving performance in a concentration-related man-
ner (e.g., Drummer et al. 2004; Grotenhermen et al. 2007;
Laumon et al. 2005; Ramaekers et al. 2004; Ramaekers et al.
2009; Ramaekers et al. 2006b).
Oral fluid has gained increasing interest as a valuable
matrix for roadside drug testing. In contrast to urine, the
advantages include ease of use, noninvasiveness, observable
sample collection, difficulty to adulterate, and demonstra-
tion of recent drug use. However, at present many immuno-
assays for detecting Δ9-tetrahydrocannabinol (THC) in oral
fluid do not have high reliability (Bosker and Huestis 2009;
Verstraete 2005). This is mainly due to THC adsorption to
the collection device, which makes recovery from the device
difficult. In addition, currently used cutoffs of point-of-
collection testing devices, although improving, are too high
to reliably detect THC in oral fluid. Furthermore, the time
window for detection is unknown, and this makes interpre-
tation of the results of oral fluid collection devices difficult.
Therefore, controlled drug administration studies are needed
(Bosker and Huestis 2009).
Standardized Field Sobriety Tests (SFST) are currently in
use in countries such as the USA and Canada for documenting
impairment in drivers suspected of driving under the influ-
ence. The SFST have been validated for detection of alcohol
impairment (Stuster 2006; Stuster and Burns 1998), but their
sensitivity to impairment caused by other drugs is relatively
unknown. Placebo-controlled studies assessing the effects of
single doses of THC, alcohol, and their combination on SFST
performance (Papafotiou et al. 2005a; Stough et al. 2006)
have reported that performance in the SFSTwas significantly
related to the administration of THC only, and THC with
alcohol. The proportion of individuals classified as impaired
doubled after THC combined with alcohol. The authors also
reported that the use of SFST resulted in the correct classifi-
cation of up to 73.9 % of participants as either impaired or not.
The one-leg stand test of the SFST was found to be the best
predictor of impairment. Performance on the SFST however
only weakly predicted driving impairment as assessed in a
driving simulator (Papafotiou et al. 2005b). SFST also failed
to predict actual driving impairment in occasional and heavy
cannabis users who received single doses of the synthetic
cannabinoid dronabinol. Single doses of dronabinol 10 and
20 mg produced driving impairment comparable to blood
alcohol concentration (BAC) levels >0.8 mg/mL as measured
in a standardized on-the-road driving test, but went undetected
in SFST assessments (Bosker et al. 2012).
The present study was designed to assess the effects of
alcohol and THC on SFST performance and to determine
the reliability of two point of collection testing devices
(Dräger Drug Test® 5000 and Securetec Drugwipe® 5) for
detecting THC in oral fluid. It was part of a larger protocol
to assess tolerance and cross-tolerance of heavy cannabis
users to the impairing effects of THC and alcohol on neuro-
cognitive performance. This data have been published else-
where (Ramaekers et al. 2011). The latter study showed that
neurocognitive performance of heavy, daily cannabis users
was impaired during alcohol intoxication, but not after THC
smoking. The absence of neurocognitive impairments in
heavy cannabis users was interpreted to show behavioral
tolerance to the impairing effects of THC. The present part
of the study focused on roadside tests for detecting cannabis
intoxication in drivers (oral fluid tests and SFST). It was
expected that single doses of THC would not affect SFST
performance in heavy cannabis users and that THC admin-
istration would be detectable in oral fluid.
Materials and methods
A summary timeline of drug and alcohol administrations,
blood and saliva collection, as well as SFST performance is
given in Fig. 1.
Participants
Twenty heavy users with mean (SE) age of 24.3 (1.4) years
participated in the study (15 males and 5 females). Partic-
ipants were recruited by advertisements at Maastricht Uni-
versity and/or at coffee shops and were paid upon
completion of the study. Before enrollment, all participants
were screened by means of a telephone interview to deter-
mine whether they qualified for the study. The inclusion
criteria were experience with cannabis (on average smoking
on 4 days/week or more during the previous year); free from
psychotropic medication; good physical health as deter-
mined by a medical examination; absence of any major
medical, endocrine, and neurological condition; body mass
index between 18 and 28 kg/m2; and written informed
consent. Furthermore, they needed to test positive for can-
nabis (THC, 11-OH-THC, and/or THCCOOH) in serum on
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screening and in urine on every testing day. The exclusion
criteria were history of drug abuse or addiction (except
cannabis) as assessed by means of a medical questionnaire
and drug urine screens, no experience with alcohol, preg-
nancy or lactation, cardiovascular abnormalities on electro-
cardiogram, excessive drinking (>25 standard alcoholic
consumptions a week), hypertension, history of or current
psychiatric disorder, and non-cigarette smokers. If partici-
pants met the inclusion criteria, they received a medical
history and a drug questionnaire. Finally, participants un-
derwent a medical examination and took part in a training
session to get familiar with the tests.
The study was conducted according to the code of ethics
on human experimentation established by the Declaration of
Helsinki (1964) and amended in Seoul (2008). Approval for
the study was obtained from the Medical Ethics committee
of the Academic Hospital of Maastricht and Maastricht
University. A permit for obtaining, storing, and administer-
ing cannabis was obtained from the Dutch drug enforcement
administration.
Study design
The study was conducted according to a double-blind,
placebo-controlled three-way design with three alcohol/
THC conditions (see Ramaekers et al. 2011). Participants
underwent three alcohol-dosing conditions that were
designed to achieve steady-state BACs of 0, 0.5, and
0.7 mg/mL during a 5-h time window. The order of
alcohol-dosing conditions was counterbalanced across par-
ticipants. In addition, participants smoked a THC cigarette
(400 μg/kg) at 3 h post-onset of alcohol dosing, in each
alcohol condition. Alcohol dosing started at 10:30 in the
morning with placebo alcohol, 0.5 or 0.7 g/kg alcohol.
Additional alcohol booster doses of about 0.1 g/kg or alco-
hol placebo were given on an as needed basis at approxi-
mately every half hour up until 4.5 h after onset of alcohol
dosing in order to keep BAC at the desired level. On
average, participants received 5.4 additional booster doses
containing alcohol (see also Ramaekers et al. 2011). Alcohol
was administered as “pure” ethanol (96 %) mixed with
orange juice to a volume of 300 mL for the initial dose.
Total volumes of booster doses mixed with orange juice
were approximately 80 mL. The marijuana cigarettes
were prepared beforehand for each individual from
stock provided by the Dutch Bureau for Medicinal Can-
nabis. Marijuana contained 11 % THC, a standard po-
tency for marijuana used recreationally and sold at
Dutch pharmacies for medical use. The total amount
of cannabis was individually weight calibrated and
mixed with tobacco to achieve a standard cigarette size
and weight. THC smoking started at 3 h post-onset of
alcohol dosing and lasted for 15 min. Participants were
instructed to smoke the cigarette according to a stan-
dardized procedure (Ramaekers et al. 2006a) in order to
minimize the participant’s possibility of dose titration
and to increase optimal absorption of THC (inhale for
4 s, hold breath for 10 s, and exhale/break for 15 s).
This sequence was repeated until the cigarettes were
smoked as completely as possible. The washout period
between treatments was at least 4 days.
Procedure
Participants were asked to refrain from any drugs except
cannabis 1 week before the medical examination until study
completion. Participants were not allowed to drink alcohol
during a 24-h period prior to testing. Participants were
allowed to continue their usual cannabis-smoking routine
during the study period. Participants were always tested for
alcohol and drugs (tetrahydrocannabinol, opiates, amphet-
amine/ecstasy, benzodiazepines, cocaine, and methamphet-
amine/ecstasy) in breath and urine, respectively, upon
arrival at the laboratory on test days. Treatments were only
administered when participants were positive for THC and
negative for all other drugs. The procedure on a test day is
described elsewhere (Ramaekers et al. 2011). The SFSTwas
performed approximately 2 h after cannabis smoking, which
is approximately 5.5 h after the first alcohol dose. In addi-
tion, baseline SFST performance was assessed in all indi-
viduals on a separate day prior to study treatments.
Fig. 1 Timeline for drug administration, Standardized Field Sobriety
Tests (SFST) performance, and blood and oral fluid collection in hours
after alcohol/smoking administration. Dashed arrows indicate time
points at which booster alcohol doses could be administered on an
as-needed basis to achieve steady BAC between 1 and 5 h after onset
of drinking
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Standardized Field Sobriety Tests
The SFST is a battery of three tests administered and eval-
uated in a standardized manner to obtain validated indicators
of impairment after alcohol consumption and establish prob-
able cause for arrest. The tests of the SFST are Horizontal
Gaze Nystagmus (HGN), Walk-and-Turn (WAT), and One-
Leg Stand (OLS).
HGN is an involuntary jerking of the eye that occurs
naturally as the eyes gaze to the side. Under normal
circumstances, nystagmus occurs when the eyes are
rotated at high peripheral angles. However, when a
person is impaired by alcohol, nystagmus is exaggerated
and may occur at lesser angles. An alcohol-impaired
person will also often have difficulty smoothly tracking
a moving object. In the HGN test, the eyes of a partic-
ipant are observed as the participant follows a slowly
moving object, such as a pen, horizontally with his or
her eyes. The examiner looks for three indicators of
impairment in each eye: if the eye cannot follow a
moving object smoothly, distinct jerking at maximum
deviation, and angle of onset of jerking within 45° of
center. If, between the two eyes, four or more clues
appear, the participant likely has a BAC of 0.8 mg/mL
or greater and was classified as impaired in the current
study. Research has shown that this test allows proper
classification of approximately 88 % of participants
(Stuster and Burns 1998).
In the WAT test, the participant is directed to take nine
steps, heel-to-toe, along a straight line. After taking the
steps, the participant must turn on one foot and return in
the same manner in the opposite direction. The examiner
looks for eight indicators of impairment: participant cannot
keep balance while listening to the instructions, participant
begins before the instructions are finished, participant stops
while walking to regain balance, participant does not touch
heel-to-toe, participant steps off the line, participant uses
arms to balance, participant makes an improper turn, or
takes an incorrect number of steps. Research has indicated
that 79 % of individuals who exhibit two or more indicators
in the performance of the test will have a BAC of 0.8 mg/mL or
greater (Stuster and Burns 1998). When participants showed
two or more signs of impairment, he/she was classified as being
impaired in the current study.
In the OLS test, the participant is instructed to stand with
one foot approximately 6 in. (15 cm) off the ground and
count aloud from 1,000 (1,000, 1,001, 1,002, etc.) for 30 s.
The examiner looks for four indicators of impairment: sway-
ing while balancing, using arms to balance, hopping to
maintain balance, and putting the foot down. Research has
indicated that 83 % of individuals who exhibit two or more
indicators in the performance of the test will have a BAC of
0.8 mg/mL or greater (Stuster and Burns 1998). The time it
took to count to 1,030 is also noted. Participants showing
two or more indicators of impairment were classified as
being impaired on this test.
In addition, an overall SFST score was generated. Partic-
ipants were classified as impaired overall whenever he/she
showed impairments on two out of three SFST. Percentages
of participants showing impairment on HGN, WAT, OLS,
and overall SFST performance were the dependent
variables.
Pharmacokinetic assessments
Oral fluid and blood samples (6 mL) were collected at
baseline, 15, 30, 45, and 60 min during the first hour
after smoking and subsequently every 30 min between 1
and 4 h after smoking. Oral fluid from half of the
participants was collected using the Dräger Drug Test®
5000 and the other half with the Securetec Drugwipe®
5 device. With the Securetec Drugwipe® 5 two results
are produced: one for oral fluid taken from the cheek
and the other from the tongue. The cutoff for cannabi-
noids as stated by the manufacturers of the Dräger Drug
Test® 5000 is 5 ng/mL and of the Securetec Drugwipe®
5 30 ng/mL. The blood sample was centrifuged, and the
resulting serum was frozen at −20°C until analysis.
THC, 11-OH-THC, and THCCOOH concentrations were
determined afterwards (Toennes et al. 2008). BAC was
assessed in serum at regular intervals (see Toennes et al.
2011) prior to SFST performance.
Statistical analysis
All statistical analyses were performed using SPSS 18.0 for
Mac. For each SFST and for the overall impairment score,
separate chi-square (χ2) tests were performed to determine
whether a relationship existed between SFST performance
and treatment conditions. SFST performance in each alcohol
condition (0.5 mg/mL+THC and 0.7 mg/mL+THC) and in
the THC-only condition (alcohol placebo) was compared to
baseline. In case of a significant treatment effect, Spear-
man’s coefficient (ρ) was calculated to determine the
strength and direction of the relationship between treatment
condition and SFST performance. A positive relationship
indicates that impairment increases with increasing dose and
a negative relationship that impairment decreases with in-
creasing dosage.
For the oral fluid tests, the percentages of false negatives
for THC (i.e., oral fluid tests that indicated the participant
was negative for THC divided through the total number of
oral fluid tests at every time point with all treatment con-
ditions collapsed) were calculated. The sensitivity was cal-
culated by dividing true positives (i.e., oral fluid tests that
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Two participants dropped out after the first treatment con-
dition for reasons unrelated to the study, and one participant
had missing data at baseline. Available data entered statisti-
cal analysis.
Standardized Field Sobriety Tests
Percentages of impaired participants on the SFST are dis-
played in Table 1. Cannabis alone was significantly related
to OLS impairment (χ204.364, df01, p00.037), and a trend
was shown for HGN (χ203.399, df01, p00.065). Both
relationships were positive (ρ00.3, p00.019; ρ00.3, p0
0.034, respectively).
The results showed that the combinations of alcohol and
cannabis were significantly related to HGN impairment
(χ207.110, df02, p00.029). A trend was shown on overall
SFST performance (χ204.939, df02, p00.085) and OLS
impairment (χ205.249, df02, p00.072). All correlations
were positive (ρ00.3, p00.004; ρ00.3, p00.018; ρ00.2,
p00.043, respectively).
Pharmacokinetic measures
The percentages of false negatives and the sensitivity of the
Dräger Drug Test® 5000 and Securetec Drugwipe® 5 and the
associated concentrations of THC, 11-OH-THC, and
THCCOOH in serum are shown in Table 2. The Dräger Drug
Test® 5000 generally performed well after acute administra-
tions of THC. The percentages of false negatives and sensi-
tivities ranged from 0–10 % and 90–100 %, respectively,
between 15 min after smoking and 3 h after smoking. How-
ever, the test was less accurate at the baseline measures before
drinking/smoking. At baseline, the percentages of false neg-
atives ranged from 22–48 % and sensitivities from 52–78 %,
Table 1 Individual impairment score on HGN, WAT, OLS and overall SFST performance during baseline and under the influence of THC in
combination with alcohol placebo, 0.5 mg/mL BAC and 0.7 mg/mL BAC






HGN WAT OLS total HGN WAT OLS total HGN WAT OLS total HGN WAT OLS total
1 – – – – 0 0 0 0 1 0 1 1 0 1 1 1
2 0 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0
3 0 1 1 1 0 0 1 0 0 1 1 1 0 1 1 1
4 0 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0
5 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
6 0 1 0 0 0 1 1 1 0 1 0 0 0 1 0 0
7 0 0 0 0 0 1 0 0 0 1 0 0 1 1 0 1
8 0 0 0 0 1 0 0 0 0 0 1 0 1 1 1 1
9 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 0 1 0 0 0 0 1 0 0 0 1 0 0 1 0 0
11 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0
12 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
13 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
15 0 0 0 0 0 0 0 0 0 0 0 0 – – – –
16 0 0 0 0 0 1 1 1 0 0 1 0 1 1 1 1
17 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
19 0 1 0 0 0 1 1 1 0 1 1 1 0 1 1 1
20 0 0 1 0 0 0 1 0 0 0 1 0 0 1 1 1
21 0 0 0 0 0 1 1 1 0 0 1 0 0 0 1 0
23 0 1 0 0 1 0 0 0 – – – – – – – –
Total (%) 0 58 21 16 15 35 50 30 11 37 53 21 28 67 44 44
HGN Horizontal Gaze Nystagmus, WAT Walk-and-Turn, OLS One-Leg Stand, SFST Standardized Field Sobriety Tests, BAC blood alcohol
concentration
Psychopharmacology (2012) 223:439–446 443
while mean THC serum concentration was 7.1 ng/mL (range,
0–20 ng/mL). The performance of the Securetec Drugwipe® 5
was less accurate. Performance was best 15 min after smoking
(8 % false negatives, sensitivity 92 %). As time after smoking
progressed, the percentages of false negatives increased and
sensitivities were low. At baseline, accuracy was low as well.
Mean BAC concentrations during SFST performance
after THC, THC+alcohol 0.5 mg/mL, and THC+alcohol
0.7 mg/mL were 0, 0.37, and 0.51 mg/mL, respectively.
Mean THC concentrations during these conditions were
13.4, 14.4, and 11.6 ng/mL, respectively.
Discussion
This study was designed to assess the effects of THC and
the combination of alcohol and THC on SFST performance.
Two oral fluid tests (Dräger Drug Test® 5000 and Securetec
Drugwipe® 5) were assessed for their accuracy in determin-
ing the presence of THC.
The SFST was mildly sensitive to the effects of cannabis
alone. A dose of 400 μg/kg body weight THC significantly
increased the percentage of participants displaying impair-
ments in OLS compared to baseline performance from 21 to
50 %. THC also increased percentage of individuals show-
ing impairment on HGN from 0 to 15 %, relative to base-
line, but this change only approached statistical significance.
WAT and the overall score on SFST did not discriminate
between THC and baseline. These findings appear in line
with previous studies that have reported a relation between
impairment on the SFST and presence of THC in blood. A
study that assessed which signs of the Drug Evaluation and
Classification evaluations predicted various drug categories
(including cannabis) at best showed that OLS contributed
significantly to the prediction, but HGN and WAT did not
(Porath-Waller et al. 2009). Papafotiou et al. (2005a)
assessed SFST performance in 40 healthy participants who
received low and high doses of THC in a placebo-controlled
study. On average, blood THC concentrations obtained after
the highest dose were comparable to serum THC concen-
trations achieved in the present study after smoking canna-
bis. Yet, THC significantly affected performance on OLS,
HGN, and WAT and appeared to be more prominent as
compared to the current study. For example, in that study
THC produced impairments on overall SFST performance
in up to 50 % of the participants (Papafotiou et al. 2005a)
but in only 30 % of the participants of the present study.
These differences may be explained in terms of differences
in cannabis use history. In the study by Papafotiou et al.
(2005a), the reported frequency of cannabis use of the
participants varied from once a week to once every 2–
6 months. The present study however only included heavy
cannabis users, who smoked cannabis on at least four occa-
sions per week. Previous studies demonstrated that heavy
cannabis users develop tolerance to the impairing effects
of THC on neurocognitive measures (Hart et al. 2001;
Ramaekers et al. 2011). It is likely that many of the partic-
ipants who participated in the present study, in part or in
Table 2 Percentages of false negatives (FN) and the sensitivity (SN)
of the Dräger Drug Test® 5000 and Securetec Drugwipe® 5 (from
cheek and tongue) and mean THC, 11-OH-THC, and THCCOOH
concentrations (nanograms per milliliter) in serum relative to time after
smoking collapsed over treatment conditions







FN SN FN SN FN SN
Baseline – – – – – – 7.1 (1.4) 50.1 (8.4) 2.9 (0.7)
−03:15 28 72 48 52 50 50 – – –
−02:45 22 78 46 54 54 46 – – –
−00:05 48 52 58 42 54 46 9.1 (1.7) 69.7 (8.5) 5.1 (1.0)
00:15 3 97 8 92 8 92 101.1 (6.1) 98.3 (10.4) 17.5 (1.5)
00:30 3 97 29 71 13 88 47.4 (3.4) 101.8 (11.0) 15.2 (1.3)
00:45 6 94 46 54 38 63 30.1 (2.0) 95.0 (10.1) 12.5 (1.0)
01:00 3 97 46 54 35 65 22.1 (1.4) 90.4 (10.3) 10.8 (0.9)
01:30 0 100 42 58 33 67 18.6 (1.2) 85.2 (10.0) 9.3 (0.8)
02:00 3 97 42 58 38 63 13.1 (1.0) 80.5 (9.6) 7.5 (0.7)
02:30 3 97 54 46 50 50 10.3 (0.8) 76.4 (9.7) 6.2 (0.6)
03:00 10 90 52 48 38 63 8.2 (0.7) 68.3 (8.9) 5.1 (0.6)
03:30 18 82 50 50 43 57 8.5 (0.7) 66.8 (7.7) 5.1 (0.6)
04:00 7 93 52 48 46 54 8.0 (0.9) 66.6 (8.3) 4.7 (0.5)
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total, developed tolerance to the impairing effects of THC as
well. In such a scenario, the failure of the SFST to demon-
strate robust effects of THC is not necessarily an indicator of
poor sensitivity, but may reflect the chronic cannabis use of
the participants.
Alternatively, one might argue that SFST were conducted
too late after cannabis administration. SFST were not per-
formed directly after smoking when impairments or THC
concentrations can be expected to be maximal. Instead, SFST
were performed 2 h after smoking in the present study, when
THC impairments are on the decline, as shown in occasional
users. It should be noted however that performance impair-
ment has repeatedly been shown to last for 3–4 h after smok-
ing THC (e.g., Ramaekers et al. 2009, 2006a). In the present
study, ratings of subjective high were also significantly ele-
vated at 2 h after smoking as reported elsewhere (Ramaekers
et al. 2011). Likewise, average THC concentrations during
SFST performance were above THC threshold levels above
which performance impairments are expected to appear in
occasional users (Ramaekers et al. 2006b). In other words,
the SFSTwere conducted well within the established “impair-
ment window” of 3–4 h post-smoking, even though the level
of impairment was submaximal. The relative lack of sensitiv-
ity of SFST for cannabis effects in the present study thus
cannot be explained by a total lack of cannabis intoxication
at the time of testing. Still, it cannot be excluded that SFST
might have been more sensitive to the effects of THC if
conducted right after smoking.
In general, the present data indicate that SFST were
mildly sensitive to the effects of THC depending on dose
and cannabis use history. It is noteworthy, however, that
SFST were unable to discriminate performance impairments
produced by dronabinol, a synthetic cannabinoid (Bosker et
al. 2012). In this placebo-controlled study, occasional and
heavy users received oral doses of dronabinol that produced
significant on-the-road driving impairments that were com-
parable to those observed after BACs >0.8 mg/mL. THC
concentrations after oral dronabinol however were much
lower (<10 ng/mL) than those achieved after smoking
cannabis. Also, THC concentrations during SFST testing
were half that in the dronabinol study compared to the
present study. This fits with the general conclusion that
SFST are mildly sensitive to the impairing effects of THC,
but that impairments may go undetected in some individu-
als, particularly at lower THC concentrations.
THC with alcohol generally increased the number of
individuals displaying impairment on HGN, OLS, and total
SFST score. Relative to baseline, percentages of impaired
individuals increased after both alcohol combinations with
THC in a dose-dependent manner. HGN was the only mea-
sure that did not reveal any impairment in participants
during baseline. It should be remembered here that all
participants included were heavy cannabis users who were
always positive for THC, also during baseline. On average,
baseline THC levels were 7.1 ng/mL. HGN may thus be an
interesting parameter to separate residual THC use from recent
THC intoxication when OLS and overall SFST performance
show impairment. In general, impairments observed after the
combination of THC and alcohol are most likely attributable
to alcohol since most of the current participants may have
developed tolerance to the impairing effects of THC on per-
formance. As such, the present data confirm the sensitivity of
the SFST for alcohol-induced impairment.
The point of collection testing devices provided mixed
results. The Dräger Drug Test® 5000 generally performed
quite well and only produced false negative in 6 % of the
measurements during 2.5 h after smoking. Securetec Drug-
wipe® 5 however performed poorly in detecting THC. The
rate of false negatives was already 8 % 15 min after smoking
and rapidly increased to about 40–50 % within the hour. The
difference in sensitivity between both devices may well be
related to differences in cutoff levels which are 5 ng/mL in
the Dräger Drug Test® 5000 and 30 ng/mL in the Securetec
Drugwipe® 5 according to the manufacturers. It should be
noted that in this study we did not determine the rate of false
positives for both devices because our participants were
never drug free. Even during baseline, low levels of THC
were present in all participants. A recent roadside study
reported about 2 % false positives for the Dräger Drug Test®
5000 and about 3 % false negatives. The sensitivity, speci-
ficity, and accuracy were 93, 71, and 90 %, respectively
(Wille et al. 2010). Together, these data indicate that point of
collection testing devices for detecting THC in oral fluid are
making large improvements relative to some of the previous
devices that were on the market (Bosker and Huestis 2009;
Ramaekers et al. 2006b). Still it has been argued in the
ROSITA-2 project that the sensitivity and specificity of oral
fluid devices should be higher than 90 % (Verstraete and
Raes 2006). According to these criteria, the Dräger Drug
Test® 5000 would still fall short on specificity (Wille et al.
2009). However, compared to the alternative matrix urine,
oral fluid drug concentrations have a better correlation with
blood concentrations and recent use of cannabis. It is there-
fore still the preferable matrix for evaluating THC presence
in drivers (Bosker and Huestis 2009; Toennes et al. 2005).
Taken together, the results indicated that the SFST were
mildly sensitive to THC use in heavy users, probably be-
cause many of the participants have developed behavioral
tolerance to THC-induced impairments. SFST were sensi-
tive to low levels of alcohol in combination with THC as
indicated by increments in the number of participants rated
as impaired on HGN, OLS, and total SFST score. The
Dräger Drug Test® 5000 achieved a high sensitivity for
THC after acute THC administration in the present study,
but the sensitivity in the case of the Securetec Drugwipe® 5
was low.
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